Nasdaq: RPRX
Royalty Pharma insiders
The officers, directors and 10% owners of Royalty Pharma plc who hold the most stock, valued at the live RPRX price.
$67.72
RPRX today −$950K (−1.38%)
Market closed. Prices as of Nov 19, 4:04 PM ET
- Ranked insiders
- 18
- Their RPRX stock
- $7.07B
- Market value
- $39.91B
- Held by ranked insiders
- 17.7%
Insiders by value of RPRX holdings
SEC ownership page| # | Insider | Role | Shares | Value | Of company | Overall rank |
|---|---|---|---|---|---|---|
| 1 | GG 1978 SICAF SIF S.A. - GG Strategic | 10% owner | 66,044,331 | $4.47B | 11.2% | Corporate |
| 2 | MGG Strategic SICAF SIF S.A. - MGG Strategic | 10% owner | 24,833,746 | $1.68B | 4.21% | Corporate |
| 3 | Pablo G. Legorreta | CEO, Chairman of the Board | 4,944,404 | $335M | 0.84% | 516th |
| 4 | George W. Lloyd | EVP, Investments & CLO | 2,724,386 | $184M | 0.46% | 939th |
| 5 | Terrance P. Coyne | EVP & CFO | 1,946,289 | $132M | 0.33% | 1225th |
| 6 | Skyeline Management Ltd | 10% owner | 1,738,760 | $118M | 0.30% | Corporate |
| 7 | James F. Reddoch | EVP & Chief Scientific Officer | 845,830 | $57.3M | 0.14% | 2308th |
| 8 | Rory B. Riggs | Director | 420,286 | $28.5M | <0.1% | 2663rd |
| 9 | Christopher Hite | EVP & Chairman, Partnering | 200,723 | $13.6M | <0.1% | 6964th |
| 10 | Gregory Norden | Director | 196,348 | $13.3M | <0.1% | 6522nd |
| 11 | Marshall Urist | EVP, Research & Investments | 149,361 | $10.1M | <0.1% | 8707th |
| 12 | Henry A. Fernandez | Director | 123,524 | $8.4M | <0.1% | 202nd |
| 13 | Errol B. Desouza | Director | 81,352 | $5.5M | <0.1% | 12946th |
| 14 | Bonnie L. Bassler | Director | 79,823 | $5.4M | <0.1% | 11424th |
| 15 | Ted W. Love | Director | 58,393 | $4.0M | <0.1% | 13629th |
| 16 | David C. Hodgson | Director | 37,873 | $2.6M | <0.1% | 13242nd |
| 17 | Vlad Coric | Director | 15,343 | $1.0M | <0.1% | 1155th |
| 18 | Carole Ho | Director | 13,103 | $887K | <0.1% | 9813th |
Only insiders worth at least $5 million in listed stock are ranked. Holdings come from each insider's latest Form 3, 4 or 5 for Royalty Pharma; see each profile for the filing.